The estimated incidence of esophageal cancer in the United States is increasing, with 17,460 new cases in 2012. [1] [2] [3] [4] [5] Overall 5-year survival has improved significantly over the past few decades but remains poor at 19%. 4, 5 The optimal treatment for locally advanced but potentially resectable esophageal cancer without distant metastases has not been definitively established by randomized controlled trials and varies in practice. 6 Complete surgical resection likely provides the best chance for cure in patients who do not have distant disease. [7] [8] [9] However, surgery is used in only 30 to 40% of resectable cases, perhaps because esophagectomy is historically associated with significant morbidity and mortality and disappointing long-term results. 7, 10 The histology distribution has changed such that adenocarcinoma is now the most common type, but squamous cell carcinoma (SCC) still accounts for 37% of esophageal cancers. 1, 3 Patients with adenocarcinoma and SCC have similar observed long-term survival across major treatment modalities, suggesting that both histologies respond simiDisclosure Information: Nothing to disclose. Dr Worni was supported by grant PBBBEP3-131567 from the Swiss National Science Foundation, and Dr Berry was supported by the NIH-funded Cardiothoracic Surgery Trials Network. larly to treatment. 11 Accordingly, esophageal cancer treatment guidelines are generally the same for both adenocarcinoma and SCC. 12 However, the benefit of surgical resection in improving survival compared to definitive chemoradiotherapy for esophageal SCC has been questioned. 13 In particular, several randomized trials have suggested that definitive chemoradiation could offer equivalent survival to treatment that involves surgery for locally advanced, non-metastatic esophageal SCC. [14] [15] [16] Because these studies have suggested that surgery does not improve survival for esophageal SCC compared to definitive chemoradiation, we sought to examine outcomes after different treatment regimens of potentially resectable mid and lower esophageal SCC using a population-based registry. The Surveillance, Epidemiology and End Results (SEER) program is the largest population-based US cancer registry, with the latest 2008 release containing 17 registries that cover 28% of the US population.
1 SEER routinely collects radiation and surgery data but lacks any information on chemotherapy use. This study tested the hypothesis that esophagectomy with or without radiation is associated with improved survival compared to definitive radiation in patients with resectable SCC of the mid and distal esophagus.
METHODS
The Institutional Review Board at Duke University approved the performance of this secondary analysis of the SEER database, which contains patient demographic, tumor characteristic, treatment (surgery, radiotherapy), survival, and cause of death data. SEER*Stat 7.0.5 was used to extract data of patients 18 years or older with locally advanced SCC of the esophagus from year 1998 to 2008. Patients with SCC of the esophagus were identified using the histology SEER codes ranging from 8050 to 8089. Patients who were diagnosed by their autopsy report or death certificate only were excluded.
The tumor-node-metastasis (TNM) stage was either directly extracted from SEER or manually recoded from available SEER variables, using the 6 th edition of the AJCC Cancer Staging Manual. 17 For patients where tumor stage T1 and T2 were not distinguishable, an additional category T1/2 was introduced. For every patient, a single tumor stage in SEER is enclosed; it is defined as clinical tumor stage if any neo-adjuvant therapy including radiotherapy, chemotherapy, hormone therapy, or immunotherapy was performed while for patients without neo-adjuvant therapy, the pathological tumor stage is reported. Additional tumor characteristics collected included tumor grade and tumor location based on the ICD-O-3 codes. Only patients with the following tumor sites were considered and grouped for the analyses: mid esophagus (C15. 1 12 The following patient characteristics were also extracted: sex, race, ethnicity, age (age Ͼ 90 years was recoded to 90 to meet patient's health identifier regulations), marital status, and time to last available reported survival time-point. Patients living longer than 5 years were right censored.
While SEER does contain information about surgery and radiation therapy, no information is available in relation to chemotherapy administration. Therefore, 4 distinct groups were defined based on the following treatments: definitive radiotherapy, preoperative radiotherapy with esophagectomy, esophagectomy only, and esophagectomy with postoperative radiotherapy. Only patients who underwent beam radiation and/or esophagectomy were analyzed; patients who had missing treatment information or had any other type of radiation or endoscopic tumor resection/ local destruction were excluded. For the main analysis, we grouped patients undergoing esophagectomy with or without radiation therapy together (others) while definitive radiation was the comparator group. We then performed a priori defined subgroup analysis comparing (1) patients undergoing esophagectomy only with patients undergoing esophagectomy and radiation therapy and (2) patients undergoing preoperative radiotherapy with patients undergoing postoperative radiotherapy.
Comparisons of patient characteristics among the treatment groups of interest were performed using chi-square test for categorical and t-test or one-way ANOVA for continuous variables. Cancer-specific survival (CSS) was assessed focusing on patients with a cause of death originating from esophageal etiology while all other deaths were right censored. In contrast, investigating overall survival (OS), all patients dying during the follow-up period were considered an event. Unadjusted survival analyses were performed both with the Kaplan-Meier method comparing survival curves with the log-rank test and with unadjusted Cox proportional hazard models. Propensity-score ad-
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CSS
ϭ cancer-specific survival OS ϭ overall survival SCC ϭ squamous cell carcinoma SEER ϭ Surveillance, Epidemiology and End Results TNM ϭ tumor-node-metastasis justed multivariable Cox proportional hazards models for CSS and OS were calculated for all treatment comparisons of interest while the propensity score was recalculated using a logistic regression model according to the underlying hypothesis. For the main analysis, surgery with or without radiation therapy served as the control group and definitive radiotherapy as the exposure group. For the comparison of surgery with radiotherapy versus surgery without radiotherapy, the latter served as the exposure group while for the comparison of postoperative versus preoperative radiotherapy, preoperative radiotherapy was considered the exposure group. The following covariates were included into the propensity score calculation: sex, age (continuous), marital status, race, ethnicity, tumor grade, location of the primary tumor, T-stage, N-stage, and year of diagnosis (grouped in 5 time-periods). 18 Because all the variables used to calculate the propensity score were also potentially associated with survival, we a priori included the same set of variables in addition to the propensity score to adjust the Cox proportional hazard regression models.
To account for the potential bias that the decision to perform adjuvant radiotherapy was made intraoperatively rather than preoperatively, we performed one set of sensitivity analyses. We therefore excluded patients with postoperative radiotherapy from the main analysis comparing radiotherapy with surgery with or without preoperative radiotherapy.
The significance level alpha was set at 0.05. Two-sided p values were calculated for all analyses. Data are presented as counts (percentages), means (standard deviations), or hazard ratios (95% confidence intervals) where appropriate. Statistical analyses were performed using STATA/SE version 11.2 (Stata Corporation, College Station, TX).
RESULTS
Overall, 2,431 patients with squamous cell carcinoma of the mid or distal esophagus who met the study inclusion criteria from 1998 to 2008 were identified in the SEER registry. Table 1 shows patient, treatment, and tumor characteristics for all patients and stratified by treatment strategy. Most tumors were located in the middle third of the esophagus and were treated with radiation alone. Compared to patients undergoing surgery with or without radiation, patients who received definitive radiation more often had mid-esophageal tumors, were older, and more likely male, black, and non-married. Of the patients treated with surgery, slightly more than half also had radiation. Most of the patients who had both surgery and radiation received radiation in the preoperative setting.
Median and 5-year survival is shown in Definitive radiotherapy versus surgery with or without radiotherapy Overall, patients treated with surgery with or without radiotherapy had significantly improved median CSS (27 versus 13 months, pϽ0.001) and median OS (20 versus 12 months, pϽ0.001) compared to definitive radiation ( Table 2 ). In both unadjusted and propensity-score adjusted Cox proportional hazard regression analysis of all patients, definitive radiation therapy was associated with worse CSS and OS compared to surgery with or without radiotherapy (Table 3 , Figure 1A ). In propensity-score adjusted subgroup analyses stratified by tumor stage, patients undergoing definitive radiation therapy had worse CSS and OS for all individual stages IIA, IIB, and III (Table 4 , Figure 1B -D).
Surgery only versus surgery and radiotherapy
Among all patients, CSS and OS were worse in patients undergoing esophagectomy only compared to patients undergoing esophagectomy and radiation therapy for both, unadjusted and propensity-score adjusted analysis (Table 3) . While this CSS and OS benefit of the combination therapy was also detected in propensity-score adjusted results for stage III patients, survival of patients with stage IIA and IIB tumors did not significantly improve when radiation was used in addition to surgery (Table 4) .
Preoperative versus postoperative radiation therapy
In subgroup analyses focusing on the comparison of preoperative and postoperative radiotherapy, no overall difference was detected for CSS and OS in both, unadjusted, and propensity-score adjusted analyses of all patients (Table 3) . In unadjusted analysis stratified by stage, only stage III patients showed better OS when preoperative radiotherapy was used. However, this survival benefit was not present after propensity-score adjustment as well (Table 4) .
Sensitivity analysis for definitive radiotherapy versus surgery with or without preoperative radiotherapy In sensitivity analysis comparing radiation therapy with surgery with or without preoperative radiotherapy, overall, patients undergoing radiation only had worse CSS (adjusted HR: 1.45, 95% CI: 1.28-1.65, p Ͻ 0.001) and OS (adjusted HR: 1.43, 95% CI: 1.28-1.60, p Ͻ 0.001). This survival benefit hold true also for patients with stage IIA, IIB, and III tumors.
DISCUSSION
Using the population-based SEER dataset, we show that patients with locally advanced but potentially resectable squamous cell cancer tumors of the esophagus have better CSS and OS for esophagectomy with or without radiation therapy over definitive radiotherapy. This finding also holds true for the tumor subgroups stage IIA, IIB, and III, even after performing propensity score adjusted multivari- able Cox proportional hazard regression analyses. We also showed that using radiation in addition to surgery improved CSS and OS for stage III tumors, no such difference was found for stage IIA and IIB tumors. Esophagectomy has historically been considered the mainstay of treatment but has disappointing long-term outcomes. 19 Many studies involving various combinations of surgery, chemotherapy, and radiation have been conducted in efforts to improve the relatively poor long-term outcomes associated with esophageal cancer, often with conflicting results. 8, [20] [21] [22] [23] [24] [25] [26] [27] [28] The National Comprehensive Cancer Network guidelines reflect the variable evidence, and allow a variety of treatments. 12 Esophagectomy is recommended for non-cervical tumors that invade the submucosa. For more locally advanced tumors that at least invade the muscularis propria, the guidelines allow for the entire spectrum of possible treatment, including esophagectomy, definitive chemoradiation, preoperative chemoradiation, and preoperative chemotherapy.
Studies have suggested that definitive chemoradiation could offer equivalent survival to treatment that involves surgery for locally advanced, non-metastatic esophageal SCC. [13] [14] [15] [16] However, this study using a population-based registry with analysis limited to locally advanced but potentially resectable SCC of the mid or distal esophagus shows that surgical resection is associated with significantly improved survival. Patients in the SEER registry from 1998 to 2008 undergoing definitive radiation therapy had worse CSS and OS compared to patients undergoing esophagectomy with or without radiation in analyses of all patients as well as analyses stratified by stage. We also found that combining radiation with surgery improved survival of stage III but not stage IIA and IIB patients. The timing of radiation did not impact survival in any of the analyses, though use in the induction setting has potential advantages of tumor downstaging that may improve resectability, improved tolerance as compared to postoperative treatment, and avoiding potential radiation damage to the esophageal replacement conduit.
The long-term survival benefit of surgical resection can be offset by increased treatment mortality when surgery is used, which may explain why randomized studies involving relatively small numbers of patients do not show a statistically significant survival benefit for surgery. 14, 15, 23 RT, radiation therapy.
Considering the increased short-term risks of surgery, a treatment regimen that selectively uses surgery only for non-complete responses or recurrences after definitive chemoradiation may avoid unnecessary morbidity in some patients. However, the use of surgery in this manner does not necessarily mean that outcomes will be equivalent as when an operation is performed immediately after the administration of chemoradiation, and should be considered only in the context of a specific protocol or trial. Regardless of how surgery is utilized, minimizing morbidity and mortality is clearly critical to optimizing outcomes. Analyses using the population-based SEER-cancer registry have the advantage of achieving wide generalizability and enough power to examine differences even among specific subgroups of non-frequent cancer sites. While the application of propensity-scoring techniques to adjust for differences in treatment allocation does allow equalizing the chance of getting either one of the treatments under consideration and improves the precision of calculated estimates, these investigations also have inherent limitations. First, data on chemotherapy administration are missing, which could account for differences in survival in the groups studied if the use of chemotherapy was not balanced between the groups. The impact of this limitation on our finding that surgical resection with or without radiation is associated with better outcomes than radiation alone is not clear. Many if not most of the patients in our study population who received radiation were likely to also have had chemotherapy, given that relatively early randomized trials failed to show a survival advantage for preoperative or postoperative radiation alone and definitive chemoradiation has been shown to be superior to radiation alone. [29] [30] [31] [32] In contrast, patients undergoing surgery without radiation may have been less likely to have received chemotherapy. Given an expected benefit of chemotherapy use, one might speculate that balancing for chemotherapy use between the two groups would even have enlarged the survival difference. Second, retrospective cohort studies are impacted by selection bias. Propensity-score adjustment is a tool to mitigate this potential bias by improving precision of the results. However, propensity-score adjustment can only be based on measured covariates and lacks the inclusion of unmeasured potential confounders like comorbidities, smoking status, or provider volume. In particular, one cannot rule out that patients who underwent definitive radiotherapy had more severe comorbidities and therefore were less likely to undergo esophagectomy, an assumption that could negatively bias the definitive radiotherapy approach. Third, information regarding beam-radiation doses and fields are not contained in the database, which might have biased outcomes comparing preoperative and postoperative radiotherapy. Fourth, tumor staging is defined by clinical assessment in patients who underwent neo-adjuvant therapy while it is based on pathological examination in patients where esophagectomy was performed without neo-adjuvant therapy. This might have led to under-or over-staging in some of the patients who underwent neoadjuvant therapy.
CONCLUSIONS
In conclusion, esophageal cancer is a relatively uncommon disease that is most commonly found when locally advanced or with distant metastases. Treatment strategies vary widely and, independent of treatment, survival is generally poor. Recommended treatment of mid and distal esophageal cancers generally does not depend on histological subtype, though some recent studies have suggested that definitive chemoradiation offers similar outcome benefits for treatments that involve surgical resection for patients with SCC. In this study using a large population-based database, we show that patients with locally advanced but potentially resectable mid and distal esophageal SCC have better outcomes when surgery is added to the treatment regimen.
Further investigations in patients with stage IIA/B tumors are warranted to decide if radiation therapy is beneficial. Therefore, esophagectomy should be considered as an integral component of the treatment algorithm whenever feasible.
